Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Psychiatric and cognitive comorbidities have been known to play a major role in human epilepsy for a long time. People with epilepsy (PWE) frequently express signs of varying psychiatric and cognitive disorders affecting their quality and quantity of life (QoL/QaoL). Over the last few years, research on behavioural comorbidities and their effect on the underlying disease have been performed in canine epilepsy. The following article reviews manifestations of comorbidities in canine epilepsy with an emphasis on patterns of clinical signs and their effects on QoL and QaoL. Cognitive and behavioural alterations in epileptic dogs are mainly represented by fear-/anxiety related behaviour and cognitive impairment (CI). Reduced trainability and altered reactions to daily situations are common results of comorbid changes posing obstacles in everyday life of owners and their dog. In addition, clinical signs similar to attention deficit hyperactivity disorder (ADHD) in humans have been reported. Canine attention-deficit-hyperactivity-disorder-like (c-ADHD-like) behaviour should, however, be evaluated critically, as there are no official criteria for diagnosis of ADHD or ADHD-like behaviour in dogs, and some of the reported signs of c-ADHD-like behaviour could be confused with anxiety-associated behaviour. Many intrinsic and extrinsic factors could potentially influence the development of behavioural and cognitive comorbidities in canine epilepsy. In particular, seizure frequency/severity, signalment and factors concerning disease management, such as pharmacotherapy and nutrition, are closely linked with the presence of the aforementioned comorbid disorders. Further studies of behavioural alterations in epileptic dogs are needed to comprehend the complexity of clinical signs and their multifactorial origin.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tvjl.2023.106060DOI Listing

Publication Analysis

Top Keywords

canine epilepsy
12
clinical signs
12
cognitive behavioural
8
behavioural comorbidities
8
psychiatric cognitive
8
cognitive comorbidities
8
comorbidities canine
8
behavioural alterations
8
alterations epileptic
8
epileptic dogs
8

Similar Publications

Corpus callosotomy (CC) is a surgical procedure for palliative epilepsy surgery targeting generalized seizures. In humans, total CC (TCC) is primarily performed in pediatric patients, whereas anterior CC is typically performed in adult patients to avoid postoperative disconnection (split-brain) syndrome, even though the antiseizure effect is inferior to TCC. In dogs, TCC may be more favorable; however, approaching and dividing the rostral part of the corpus callosum (genu) through a previously described bilateral rostrotentorial (dorsal) approach is challenging, particularly in meso- and dolichocephalic and/or large-breed dogs.

View Article and Find Full Text PDF

In addition to characteristic and easily identifiable behavioural signs-namely epileptic seizures-electroencephalography (EEG) has long been a standard component of epilepsy diagnosis protocols. In veterinary practice, EEG is typically performed in a semi-invasive manner, using subcutaneous electrodes and sedation. Here, we propose that the non-invasive polysomnography protocol, originally developed for basic research, can serve as a more welfare-friendly yet informative alternative for assessing epileptic brain activity in dogs.

View Article and Find Full Text PDF

Background: Current diagnosis of brain disease in dogs is dependent on imaging and cerebrospinal fluid (CSF) analysis, including total nucleated cell counts and albumin concentrations.

Hypothesis/objectives: To determine whether multiplex cytokine/chemokine (Ct/Cm) analysis can differentiate among dogs with meningoencephalitis of unknown origin (MUE), idiopathic epilepsy (IE), and brain neoplasia.

Animals: Client owned dogs diagnosed with brain disease with MRI and CSF diagnostics.

View Article and Find Full Text PDF

Purpose: ADAM23 is involved in neuronal excitability and interacts with LGI1, a known genetic risk factor for focal epilepsy. While ADAM23 has been linked to canine seizures, a recent gene-burden meta-analysis first nominated it as a risk gene for epilepsy in humans. Building on these findings, our study aimed to explore the significance of truncating ADAM23 variants in deeply phenotyped individuals with diverse seizure disorders.

View Article and Find Full Text PDF

While the efficacy of repetitive transcranial magnetic stimulation (rTMS) has been explored in humans and, to a lesser extent, in dogs with epilepsy, further clinical studies are required to assess the potential antiseizure effect of this non-invasive neurostimulation technique. The objective was to assess the antiseizure effect and safety of a novel three-day rTMS protocol in dogs with drug-resistant idiopathic epilepsy. A single-blinded, randomized, sham-controlled clinical trial was conducted by randomly allocating 20 dogs with drug-resistant idiopathic epilepsy or epilepsy of unknown origin into active ( = 10) or sham ( = 10) rTMS.

View Article and Find Full Text PDF